Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200547 | 0.88 | KMT2A (0.50) | KMT2AMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL10953243 | 0.86 | HSD17B10 (0.62) | KMT2AMAPK1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL10334085 | 0.85 | KMT2A (0.56) | KMT2AMAPK1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL2199345 | 0.82 | KMT2A (0.54) | KMT2AMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL9383327 | 0.82 | RORC (0.61) | KMT2AMAPK1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL10730672 | 0.81 | MAPK1 (0.69) | KMT2AMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL2855075 | 0.79 | MAPK1 (0.59) | KMT2AMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL10902402 | 0.77 | NPSR1 (0.71) | KMT2AMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL2197547 | 0.77 | ALDH1A1 (0.46) | MAPK1MAPTNPC1RAB9AGAA | |
| SCHEMBL14744568 | 0.77 | LMNA (0.53) | KMT2AMAPK1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115728-B | Triazole substituted aminobenzophenone compounds | LEO PHARMA AS | 2012-12-19 | — | — | CN | disclosed |
| US-8293772-B2 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2012-10-23 | — | — | US | disclosed |
| EP-1828148-B1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| CN-101115728-A | Triazole substituted aminobenzophenone compounds | LEO PHARMA AS (DK) | 2008-01-30 | — | — | CN | disclosed |
| EP-1828148-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063585-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | NFKBIA, UACA, CYP1B1 | KMT2A 3297/4885MAPK1 1523/4885MAPT 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.